Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.
Pfizer
Pfizer Inc (PFI). announced that the European Commission (EC) has amended the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to include the prevention of RSV-induced lower respiratory tract disease (LRTD) in people aged 18 to 59. This broadens the prior license for […]
At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.
The United States FDA grants accelerated approval for Pfizer’s therapy for the treatment of blood cancer (type)-affected patients which is difficult to treat.
